8F02
SARS-CoV-2 Main Protease (Mpro) in Complex with ML2006a4
8F02 の概要
エントリーDOI | 10.2210/pdb8f02/pdb |
関連するPDBエントリー | 7SET 7SF1 7SF3 7SFB 7SFH 7SFI 7SGH 7U92 7UUG 7UUP 8EZV 8EZZ |
分子名称 | 3C-like proteinase nsp5, (1R,2S,5S)-N-{(2S,3R)-4-(3,3-dimethylazetidin-1-yl)-3-hydroxy-4-oxo-1-[(3S)-2-oxopiperidin-3-yl]butan-2-yl}-6,6-dimethyl-3-[3-methyl-N-(trifluoroacetyl)-L-valyl]-3-azabicyclo[3.1.0]hexane-2-carboxamide (3 entities in total) |
機能のキーワード | sarscov2, sars-cov-2, coronavirus, main protease, protease, mpro, 3c-like proteinase, cl3pro, inhibitor, complex, covalent, adduct, m2006a4, ketoamide, azetidine, peptidomimetic, viral protein |
由来する生物種 | Severe acute respiratory syndrome coronavirus 2 |
タンパク質・核酸の鎖数 | 1 |
化学式量合計 | 34455.26 |
構造登録者 | |
主引用文献 | Westberg, M.,Su, Y.,Zou, X.,Huang, P.,Rustagi, A.,Garhyan, J.,Patel, P.B.,Fernandez, D.,Wu, Y.,Hao, C.,Lo, C.W.,Karim, M.,Ning, L.,Beck, A.,Saenkham-Huntsinger, P.,Tat, V.,Drelich, A.,Peng, B.H.,Einav, S.,Tseng, C.K.,Blish, C.,Lin, M.Z. An orally bioavailable SARS-CoV-2 main protease inhibitor exhibits improved affinity and reduced sensitivity to mutations. Sci Transl Med, 16:eadi0979-eadi0979, 2024 Cited by PubMed: 38478629DOI: 10.1126/scitranslmed.adi0979 主引用文献が同じPDBエントリー |
実験手法 | X-RAY DIFFRACTION (2 Å) |
構造検証レポート
検証レポート(詳細版)をダウンロード